About the Company
poseida therapeutics, inc. is currently developing car-t and gene therapy products for cancer and orphan diseases. spinout of transposagen biopharmaceuticals early this year, poseida is also collaborating with j&j’s janssen to develop allogeneic car-t therapies against cancer. poseida boasts best-in-class genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes and/or technologies. proprietary tools include piggybac™ dna modification system, nextgen™ crispr, xtn™ talen and footprint-free™ gene editing system, which are clean (synthetic and virus-free) and can be surgically precise. poseida aims to shuttle the first car-t and gene therapy product candidates into phase i clinical trials in early 2016. poseida is now hiring and searching for ambitious and motivated scientists desiring a fast-paced work environment with diverse research opportunities in the field of cellular and gene therapy.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PSTX News
Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological ...
Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth quarter revenues increased to $25.0 million, up from $10.1 million in the same period of 2022. Annual Revenue Decline: Full year revenues decreased to $64.7 million from $130.5 million ...
Poseida spikes after FDA orphan status for CAR-T therapy
Update 9:40 PM EST: Adds comments from Poseida. Shares of Poseida Therapeutics (NASDAQ:PSTX) traded higher on Wednesday after ...
Poseida Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Buy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical Updates
In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Poseida Therapeutics (PSTX – Research Report), ...
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.39 per share a year ago. These ...
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments ...
PSTX Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for ...
Poseida Therapeutics, Inc.: Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
solid tumor settings P-FVIII-101 gene therapy data presented at ASH and Company to host Gene Therapy R&D Day April 17, 2024 SAN DIEGO, March 7, 2024 /PRNewswire/ -- Poseida Therapeutics ...
Poseida Therapeutics, Inc.: Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Data Describing Activity of P-BCMA-ALLO1 in BCMA-Experienced Patients to be Presented at Upcoming AACR Meeting SAN DIEGO, March 13, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), ...
Loading the latest forecasts...